Table 1. Patient (n = 41) and lesion (n = 45) characteristics.

Gender (male, n, %)	25/41 (61 %)
Age (years, mean, SD)	60.4 (± 11)
Disease duration (years), median (range)	25 (1–50)
Type of IBD, n (%)
Ulcerative colitis	33 (80 %)
Crohn's disease	8 (20 %)
ASA class, n (%)
I	5/41 (12 %)
II	23/41 (56 %)
III	11/41 (27 %)
IV	2/41 (5 %)
Primary sclerosing cholangitis, n (%)	0
Stricturing disease, n (%)	0
Preceding failed endoscopic treatment, n (%)	9 (20 %)
Location of tumor, n (%)
Rectum	23 (51.1 %)
Sigmoid & rectosigmoid	10 (22.2 %)
Descending colon	5 (11.1 %)
Transverse colon	4 (8.8 %)
Ascending colon & cecum	3 (6.6 %)
Tumor size (mm, median, IQR)	30 (23–42)
Paris classification, n (%)
Is	2 (4 %)
IIa	24 (53 %)
IIb	17 (38 %)
IIa + IIc	1 (2 %)
IIa + Is	1 (2 %)
Pre-ESD diagnosis based on biopsy, n (%)
Low-grade dysplasia or adenoma	27 (62.7 %)
High-grade dysplasia	9 (20.9 %)
Sessile serrated polyps/adenomas	5 (11.6 %)
Intramucosal cancer	2 (4.7 %)
No biopsy	2
Presence of ulcer at the lesion, n (%)	0
Degree of submucosal fibrosis, n (%)
F0 (none)	12 (26.7 %)
F1 (mild)	15 (33.3 %)
F2 (severe)	18 (40.0 %)
Procedure time (min, median, IQR)	93 (IQR 66–123)
Procedure setting, n (%)
Outpatient setting	22/45 (49 %)
Overnight observation	18/45 (40 %)
Admission > 24 hours	5/45 (11 %)

SD, standard deviation; IBD, inflammatory bowel disease; ASA, American Society of Anesthesiologists; ESD, endoscopic submucosal dissection; IQR, interquartile range.